This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
by Zacks Equity Research
Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.
Chemed (CHE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemed (CHE) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 8.13% and 0.79%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare
by Zacks Equity Research
Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.
OPCH or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Faces Macroeconomic Woes, Tough Competition
by Zacks Equity Research
Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.
OPCH vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
OPCH vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OPCH vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q2 Earnings Miss Estimates, '23 EPS View Down
by Zacks Equity Research
Chemed's (CHE) second-quarter 2023 performance reflects strength in the VITAS segment, while expenses weigh on margins.
Chemed (CHE) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Chemed (CHE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Chemed (CHE) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -7.47% and 1.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.
4 Stocks to Hold in a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.
Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?
by Zacks Equity Research
Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Stryker (SYK) Q1 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter (BAX) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
Baxter's (BAX) first-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
West Pharmaceutical (WST) Q1 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance
by Zacks Equity Research
Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.